The FDA has approved Life Biosciences to begin a first‑in‑human study testing an in‑eye gene‑therapy reprogramming approach intended to reverse cellular aging markers. The trial will enroll a small cohort of patients with glaucoma and deliver viruses carrying transient reprogramming factors to one eye under doxycycline‑inducible control. The company and affiliated investigators emphasize tight safety controls: gene expression is switchable with an oral antibiotic and treatment durations are limited. Reprogramming aims to reset epigenetic age signatures but carries oncogenic risk in preclinical models, prompting intensive regulatory scrutiny. This approval marks a high‑profile test of reprogramming concepts in humans and will inform safety monitoring, dosing strategies and translational risk assessments for broader regenerative medicine applications.